Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 8, 2004 - Issue 2
Submit an article Journal homepage
113
Views
19
CrossRef citations to date
0
Altmetric
Review

Recent advances towards identification of new drug targets for Mycobacterium tuberculosis

Kirti Sharma Institute of Genomics and Integrative Biology, Mall Road, Near Jubilee Hall, Delhi 110 007, India. [email protected]; [email protected]
,
Puneet Chopra Institute of Genomics and Integrative Biology, Mall Road, Near Jubilee Hall, Delhi 110 007, India. [email protected]; [email protected]
&
Yogendra Singh Institute of Genomics and Integrative Biology, Mall Road, Near Jubilee Hall, Delhi 110 007, India. [email protected]; [email protected]
Pages 79-93 | Published online: 02 Mar 2005

Bibliography

  • SNIDER DE Jr, RAVIGLIONE M, KOCHI A: Tuberculosis: pathogenetic, protection, and control. Bloom BR (Ed.), American Society for Microbiology, Washington DC, USA (1994):2–11.
  • KOCHI A: WHO report on the tuberculosis epidemic (1996).
  • CULLITON BJ: Drug-resistant TB may bring epidemic. Nature (1992) 356:473. Erratum 737.
  • STURGILL-KOSZYCKI S, SCHLESINGER PH, CHAKRABORTY P et al.: Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science (1994) 263:678–681.
  • ••Report elucidating inhibition of vesicular acidification as a survival strategy of M tuberculosis
  • ARMSTRONG JA, HART PD: Phagosome—lysosome interaction in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual non-fusion pattern and observation on bactericidal survival.j Exp. Med. (1975) 142:1–16.
  • NOSS EH, HARDING CV, BOOM WH: Mycobacterium tuberculosis inhibits MHC Class II antigen processing in murine bone marrow macrophages. Cell. brimunol. (2000) 201:63–74.
  • FERRARI G, LANGEN H, NAITO M, PIETERS J: A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell (1999) 97:435–447.
  • GHOSH S, PAL S, DAS S, DASGUPTA SK, MAJUMDAR S: Lipoarabinomannan induced cytotoxic effects in human mononuclear cells. FEMS Immunol. Med. Microbial. (1998) 21:181–188.
  • ZAHRT TC: Molecular mechanisms regulating persistent Mycobacterium tuberculosis infection. Microbes Infect. (2003) 5:159–167.
  • WINDER G, COLLINS PB: Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis J. Gen. Microbiol (1970) 63:41–48.
  • ••A report deciphering the mechanism ofaction of INH.
  • BANERJEE A, DUBNAU E, QUEMARD A et al: inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis Science (1994) 263:227–230.
  • TELENTI A, IMBODEN P, MARCHESI F, LOWRIE D, COLE S, COLSTON MJ: Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis Lancet (1993) 341:647–650.
  • ZIMHONY O, COX JS, WELCH JT, VILCHEZE C, JACOBS WR Jr: Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FAST) of Mycobacterium tuberculosis Nat. Med. (2000) 6:1043–1047.
  • ••A report unravelling the mechanism ofaction of PZA.
  • TAKAYAMA K, KILBURN JO: Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob. Agents Chemother (1989) 33:1493–1499.
  • WINDER FG: The antibacterial action of streptomycin, isoniazid and PAS. In: Chemotherapy of tuberculosis Barry VC (Ed.), Butterworth & Co. Ltd, London, UK (1964):111–149.
  • ZHANG Y, TELENTI A: In: Molecular Genetics of mycobacteria. Hatfull GF, Jacobs WR Jr (Eds), ASM Press, Washington DC, USA (2000):235–254.
  • RANDO RR: On the mechanism of action of antibiotics which act as irreversible enzyme inhibitors. Biochem. Pharmacol (1975) 24:1153–1160.
  • JACOBS MR: Activity of quinolones against mycobacteria. Drugs (1995) 58:19–22.
  • GILLESPIE SH: Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother: (2002) 46:267–274.
  • WORLD HEALTH ORGANIZATION: Tuberculosis Fact Sheet (No. 104) 2000.
  • SNIDER DE JR, CASTRO KG: The global threat of drug-resistant tuberculosis. N Engl. J. Med. (1998) 338:1689–1690.
  • MAHMOUDI A, ISEMAN MD: Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA (1993) 270:65–68.
  • ZHANG Y, MARIO AL: Tuberculosis drug targets. Curr. Drug Targets (2002) 3:131–154.
  • COLE ST, BROSCH R, PARKHILL J et al: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 393:537–544
  • ••Complete genome sequence of M tuberculosis.
  • SASSETTI CM, BOYD D H, RUBIN EJ: Genes required for mycobacterial growth defined by high-density mutagenesis. Microbiol (2003) 48:77–84.
  • BUCHMEIER N, BLANC-POTARD A, EHRT S, PIDDINGTON D, RILEY L, GROISMAN EA: A parallel intraphagosomal survival strategy shared by Mycobacterium tuberculosis and Salmonella enterica. Mol. Microbiol (2000) 35:1375–1382.
  • GOLD B, RODRIGUEZ GM, MARRAS SA, PENTECOST M, SMITH I: The Mycobacterium tuberculosis IdeR is a dual functional regulator that controls transcription of genes involved in iron acquisition, iron storage and survival in macrophages. Mol Mier-chid. (2001) 42:851–865.
  • DE VOSS JJ, RUTTER K, SCHROEDER BG, SU H, ZHU Y, BARRY CE III: The salicylate-derived mycobactein siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc. Natl. Acad. Sci. USA (2000) 97:1252–1257.
  • •Report indicating the importance of iron uptake in the survival of M tuberculosis.
  • HONDALUS MK, BARDAROV S, RUSSELL R, CHAN J, JACOBS WR Jr, BLOOM BR: Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect. Inman. (2000) 68:2888–2898.
  • PAVELKA MS Jr, CHEN B, KELLEY CL, COLLINS FM, JACOBS WR Jr: Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis. Infect. Inman. (2003) 71:4190–4192.
  • SMITH DA, PARISH T, STOKER NG, BANCROFT GJ: Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect. Inman. (2001) 69:1142–1150.
  • JACKSON M, PHALEN SW, LAGRANDERIE M et al.: Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect. Inman. (1999) 67:2867–2873.
  • PEREIRA JH, CANDURI F, DE OLIVEIRA JS, DA SILVEIRA NJ, BASSO LA, PALMA MS: Structural bioinformatics study of EPSP synthase from Mycobacterium tuberculosis. Biochem. Biophys. Res. Commun. (2003) 312:608–614.
  • SAMBANDAMURTHY VK, WANG X, CHEN B et al: A pantothenate auxotrophs of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat. Med. (2002) 8:1171–1174.
  • •This report highlights the importance of pantothenate biosynthesis in the pathogenesis of M tuberculosis
  • HUOVINEN P, SUNDSTROM L, SWEDBERG G, SKOLD O: Trimethoprim and sulfonamide resistance. Antimicrob. Agents Chemother. (1995) 39:279–289.
  • LOCHER HH, SCHLUNEGGER H, HARTMAN PG, ANGEHRN P, THEN RL: Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone. Antimicrob. Agents Chemother: (1996) 40:1376–1381.
  • GLICKMANN MS: A novel mycolic acidcyclopropane synthetase is required for cording, persistance and virulence of Mycobacterium tuberculosis. Ma Cell. (2000) 5:717–727.
  • MCKINNEY JD, HONER ZU BENTRUP K, MUNOZ-ELIAS EJ et al.: Persistance of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature (2000) 406:735–738.
  • ••The importance of isocitrate lyase in themycobacterial persistence and virulence was illustrated.
  • RAYNAUD C, GUILHOT C, RAUZIER Jet al.: Phospholipases C are involved in the virulence of Mycobacterium tuberculosis. Ma Microbic] (2002) 45:203–217.
  • BOSHOFF HI, REED MB, BARRY CE III, MIZRAHI V: DnaE2 polymerase contributes to M vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis Cell (2003) 113:183–193.
  • ••A recent report showing the importance ofincreased mutation rates in the generation of more fit' mycobacterial strains.
  • DAHL JL, KRAUS CN, BOSHOFF HI et al.: The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc. Nat] Acad. Sci. USA (2003) 100:10026–10031.
  • SUN Z, ZHANG Y: Spent culture supernatant of Mycobacterium tuberculosis H37Ra improves viability of aged cultures of this strain and allows small inocula to initiate growth. Bacteria (1999) 181:7626–7628.
  • ZHANG Y, YANG Y, WOODS A et al.:Resuscitation of dormant Mycobacterium tuberculosis by phospholipids or specific peptides. Biochem. Biophys. Res. Commun. (2001) 284:542–547.
  • MUKAMOLOVA GV, KAPRELYANTS AS, YOUNG DI et at A bacterial cytokine. Proc. Natl. Acad. Sri. USA (1998) 95:8916–8921.
  • CHOPRA P, MEENA LS, SINGH Y: New drug targets of Mycobacterium tuberculosis. Indian Med. Res. (2003) 117:1–9.
  • COHEN P: Protein kinases - the major drug targets of the twenty-first century? Nat. Rev Drug Discov (2002) 1:309–315.
  • LYON MA, DUCRUET AP, WIPE P, LAZO JS: Dual-specificity phosphatases as targets for antineoplastic agents. Nat. Rev Drug Discov. (2002) 1:961–976.
  • VAN HUIJSDUIJNEN RH, BOMBRUN A, SWINNEN D: Selecting protein tyrosine phosphatases as drug targets. Drug Discov. Today (2002) 7:1013–1019.
  • MCCLUSKEY A, SAKOFF JA: Small molecule inhibitors of serine/ threonine protein phosphatases. Mini Rev Med. Chem. (2001) 1:43–55.
  • HUIJSDUIJNEN RHV, BOMBRUN A, SWINNEN D: Selecting protein tyrosine phosphatases as drug targets. Drug Discov. Today (2002) 7:1013–1019.
  • PATHAK MK, YI T: Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. .1. Immuna (2001) 167:3391–3397.
  • AV-GAY Y, EVERETT M: The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis. Trends Microbia (2000) 8:234–244.
  • HAKANSSON SE, GALYOV EE, ROSQVIST R, WOLF-WATZ H: The Yersinia YpIcA Ser/Thr kinase is translocated into and subsequently targeted to the inner surface of the Hela cell plasma membrane. Ma. Microbia (1996) 20:593–603.
  • •Study indicating the importance of eukaryotic-type serine/threonine kinase in the bacterial pathogenesis.
  • DREWS S J, HUNG F, AV-GAY Y: A protein kinase inhibitor as an antibacterial agent. FEMS Microbia Lett. (2001) 205:369–374.
  • CHABA R, RAJE M, CHAKRABARTY PK:Evidences that a eukaryotic-type serine/ threonine protein kinase from Mycobacterium tuberculosisregulates morphological changes associated with cell division. Eur. I Biochent. (2002) 269:1078–1085.
  • ORTIZ-LOMBARDIA M, POMPEO F, BOITEL B, ALZARI PM: Crystal structure of the catalytic domain of the PknB serine/threonine kinase from Mycobacterium tuberculosis I Biol. Chem. (2003) 278:13094–13100.
  • YOUNG TA, DELAGOUTTE B, ENDRIZZI JA, FALICK AM, ALBERT: Structure of Mycobaterium tuberculosis PknB supports a universal activation mechanism for Ser/Thr protein kinases. Nat. Struct. Biol. (2003) 10:168–174.
  • AV-GAY Y, JAMIL S, DREWS SJ: Expression and characterization of the Mycobacterium tuberculosis serine/threonine protein kinase PknB. Infect. Immun. (1999) 67:5676–5682.
  • KOUL A, CHOIDAS A, TYAGI AK et al.:Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: characterization and localization. Microbiology(2001) 147:2307–2314.
  • SHARMA K, CHANDRA H, GUPTA PK et al.: PknH, a transmembrane Hank's type serine/threonine kinase from Mycobacterium tuberculosis is differentially expressed under stress conditions. FEMS Microbia Lett. (2004). In Press.
  • MOLLE V, KREMER L, GIRARD-BLANC C, BESRA GS, COZZONE AJ, PROST JF: An FHA phosphoprotein recognition domain mediates protein EmbR phosphorylation by PknH, a Ser/Thr protein kinase from Mycobacterium tuberculosis. Biochemistry (Mosc) (2003) 42:15300–15309.
  • COWLEY SC, AV-GAY Y: Promoter activity and protein localization in Mycobacterium spp. using green fluorescent protein. Gene (2001) 264:225–231.
  • AGARWAL N, TYAGI AK: Role of 5 --TGN-3 motif in the interaction of mycobacterial RNA polymerase with a promoter of 'extended-10' class. FEMS Microbia Lett. (2003) 225:75–83.
  • BERT KLEBL: Target driven drug discovery in TB, employing the mycobacterial kinase PknG. Gordon Research Conference on Tuberculosis Drug Discovery. Oxford, UK (2003).
  • FU Y, GALAN JE: A Salmonella protein antagonizes Rac-1 and Cdc42 to mediate host cell recovery after bacterial invasion. Nature (1999) 401:293–297.
  • BLISKA JB, GUAN K, DIXON JE, FALKOW S: Tyrosine phosphatase hydrolysis of host proteins by an essential Yersinia virulence determinant. Proc. Natl. Acad. Sci USA (1991) 88:1187–1191.
  • KUSNER DJ, HALL CE SCHLESINGER LS: Activation of phospholipase D is tightly coupled to the phagocytosis of Mycobacterium tuberculosis or opsonized zymosan by human macrophages. Exp. Med. (1996) 184:585–595.
  • DE CAMILLI P, EMR SD, MCPHERSON PS, NOVICK P: Phosphoinositides as regulators of membrane traffic. Sdence (1996) 271:1533–1539.
  • MALIK ZA, THOMPSON CR, HASHIMI S, PORTER B, IYER SS, KUSNER DJ: Cutting edge: Mycobacterium tuberculosis blocks Ca2' signaling and phagosome maturation in human macrophages via specific inhibition of sphingosine kinase. Immunol. (2003) 170:2811–2815.
  • HESTVIK AL, HMAMA Z, AV-GAY Y: Kinome analysis of host response to mycobacterial infection: a novel technique in proteomics. Infect. Immun. (2003) 71:5514–5522.
  • VERGNE I, CHUA J, DERETIC V: Tuberculosis toxin blocking phagosome maturation inhibits a novel Ca2V calmodulin-PI3K hVPS34 cascade. Exp. Med. (2003) 198:653–659.
  • SINGH B, SINGH G, TRAJKOVIC V, SHARMA P: Intracellular expression of Mycobacterium tuberculosis-specific 10-kDa antigen down-regulates macrophage B7.1 expression and nitric oxide release. Clin. Exp. Immuna (2003) 134:70–77.
  • KOUL A, CHOIDAS A, TREDER M et al.: Cloning and characterization of secretory tyrosine phosphatase of Mycobacterium tuberculosis Bacterioi (2000) 182:5425–5432.
  • SINGH R, RAO V, SHAKILA H et al.: Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs. Ma Microbial. (2003) 50:751–762.
  • ••First study unveiling the importance oftyrosine phosphatase in the virulence of M tuberculosis
  • COWLEY SC, BABAKAIFF R, AV-GAY Y:Expression and localization of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA. Res. Microbial. (2002) 153:233–241.
  • CHOPRA P, SINGH B, SINGH R et al.: Phosphoprotein phosphatase of Mycobacterium tuberculosis dephosphorylates serine-threonine kinases PknA and PknB. Biochem. Biophys. Res. Commun. (2003) 311:112–120.
  • BOITEL B, ORTIZ-LOMBARDIA M, DURAN R et al.: PknB kinase activity is regulated by phosphorylation in two Thr residues and dephosphorylation by PstP, the cognate phospho-Ser/Thr phosphatase, in Mycobacterium tuberculosis. Ma Microbia (2003) 49:1493–1508.
  • HOCH JA: Two-component and phosphorelay signal transduction. Curr. Opin. Microbial. (2000) 3:165–170.
  • PARISH T, SMITH DA, KENDALL S, CASALI N, BANCROFT GJ, STOKER NG: Deletion of two-component regulatory systems increases the virulence of Mycobacterium tuberculosis. Infect. Immun. (2003) 71:1134–1140.
  • PEREZ E, SAMPER S, BORDAS Y, GUILHOT C, GICQUEL B, MARTIN C: An essential role for phoP in Mycobacterium tuberculosis virulence. Ma Microbia (2001) 41:179–187.
  • ZAHRT TC, DERETIC V: An essential two-component signal transduction system in Mycobacterium tuberculosis. Bacteria (2000) 182:3832–3838.
  • DASGUPTA N, KAPUR V, SINGH KK et al.: Characterization of a two-component system, devR-devS, of Mycobacterium tuberculosis Tuber. Lung Dis. (2000) 80:141–159.
  • GLICKMAN MS, JACOBS WB Jr: Microbial pathogenesis of Mycobacterium tuberculosis; dawn of a discipline. Cell (2001) 104:477–485.
  • NIEDERWEIS M: Mycobacterial porins - new channel proteins in unique outer membranes. Ma Microbial. (2003) 49:1167–1177.
  • DEVERGNE O, EMILIE D, PEUCHMAUR M, CREVON MC, DIAGAY MF, GALANAUD P: Production of cytokines in sarcoid lymph nodes: preferential expression of interleukin-1-13 and interferon-y genes. Hum. Patha (1992) 23:317–323.
  • CHAN J, RAN X, HUNTER SW, BRENNAN PJ, BLOOM BR: Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect. Inman. (1991) 59:1755–1761.
  • BERTHET FX, LAGRANDERIE M, GOUNON P et al.: Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science (1998) 282:759–762.
  • COX JS, CHEN B, MCNEIL M, JACOBS WR Jr: Complex lipid determines tissue specific replication of Mycobacterium tuberculosis in mice. Nature (1999) 402:79–83.
  • DUBNAU E, CHAN J, RAYNAUD C et al.: Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Ma Microbial. (2000) 36:630–637.
  • MAY, STERN RJ, SCHERMAN MS et al.: Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob. Agents Chemother. (2001) 45:1407–1416.
  • HOU JY, GRAHAM JE, CLARK-CURTISS JE: Mycobacterium avium genes expressed during growth in human macrophages detected by selective capture of transcribed sequences (SCOTS). Infect. Immun. (2002) 70:3714–3726.
  • CHAKRABARTY AM: Nucleoside diphosphate kinase: role in bacterial growth, virulence, cell signalling and polysaccharide synthesis. Ma Microbia (1998) 28:875–882.
  • CHOPRA P, SINGH A, KOUL A et al.: Cytotoxic activity of nucleoside diphosphate kinase secreted from Mycobacterium tuberculosis. Eur.j Biochem. (2003) 270:625–634.
  • COLLINS DM, KAWAKAMI RP, DE LISLE GW, PASCOPELLA L, BLOOM BR, JACOBS WR Jr: Mutation of the principal 6 factor causes loss of virulence in a strain of the Mycobacterium tuberculosis complex. Proc. Nati Acad. Sci. USA (1995) 92:8036–8040.
  • ••Report showing the significance ofmycobacterial 6 factor in their virulence.
  • STEYN AJ, COLLINS DM, HONDALUS MK, JACOBS WR Jr, KAWAKAMI RP, BLOOM BR: Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth. Proc. Nati Acad. Sci. USA (2002) 99:3147–3152.
  • CHEN P, RAFAEL E, RUIZ QING LI, RICHARD FS, BISHAI WR: Construction and characterization of a Mycobacterium tuberculosis mutant lacking the alternate 6 factor gene, sigE Infect. Inman. (2000) 68:5575–5580.
  • DOUKHAN L, PREDICH M, NAIR G et al.: Genomic organization of the mycobacterial 6 gene cluster. Gene (1995) 165:67–70.
  • WU QL, KONG D, LAM K, HUSSON RN: A mycobacterial extracytoplasmic function 6 factor involved in survival following stress. Bacteria (1997) 179:2922–2929.
  • RAMAN S, SONG T, PUYANG X, BARDAROV S, JACOBS WR Jr, HUSSON RN: The alternative 6 factor SigH regulates major components of oxidative and heat stress responses in Mycobacterium tuberculosis. Bacteria (2001) 183:6119–6125.
  • SAREEN D, NEWTON GL, FAHEY RC, BUCHMEIER NA: Mycothiol is essential for growth of Mycobacterium tuberculosis Erdman. Bacteria (2003) 185:6736–6740.
  • BANU S, HONORE N, SAINT-JOANIS B, PHILPOTT D, PREVOST MC, COLE ST: Are the PE-PGRS proteins of Mycobacterium tuberculosis variable surface antigens? Ma Microbia (2002) 44:9–19.
  • BRENNAN MJ, DELOGU G, CHEN Y et al.: Evidence that mycobacterial PE-PGRS proteins are cell surface constituents that influence interactions with other cells. Infect. Immun. (2001) 69:7326–7333.
  • DELOGU G, BRENNAN MJ: Comparative immune response to PE and PE-PGRS antigens of Mycobacterium tuberculosis. Infect. Immun. (2001) 69:5606–5611.
  • SINGH KK, ZHANG X, PATIBANDLA AS, CHIEN P Jr, LAAL S: Antigens of Mycobacterium tuberculosis expressed during preclinical tuberculosis: serological immunodominance of proteins with repetitive amino acid sequences. Infect. Immun. (2001) 69:4185–4191.
  • RAMAKRISHNAN L, FEDERSPIEL NA, FALKO WS: Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS family. Science (2000) 288:1436-1439. First report establishing a direct role of some PE-PGRS proteins in the virulence of M tuberculosis.
  • COLE ST: Learning from the genome sequence of Mycobacterium tuberculosis H37Rv. FEBS Lett. (1999) 452:7–10.
  • FLORES J, ESPITIA C: Differential expression of PE and PE-PGRS genes in Mycobacterium tuberculosis strains. Gene (2003) 318:75–81.
  • LI Z, KELLEY C, COLLINS F, ROUSE D, MORRIS S: Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. Infect. Dis. (1998) 177:1030–1035.
  • EDWARDS KM, CYNAMON MH, VOLADRI RK et al: Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Respit: Crit. Care Med. (2001) 164:2213–2219.
  • SKJOT RLV, OETTINGER T, ROSWNKRANDS I et al: Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect. Immun. (2000) 68:214–220.
  • WARDS BJ, DE LISLE GW, COLLINS DM: An esat6 knockout mutant of Mycobacterium bovis produced by homologous recombination will contribute to the development of a live tuberculosis vaccine. Tuber. Lung D (2000) 80:185–189.
  • COPP BR: Antimycobacterial natural products: Nat. Prod. Rep. (2003) 20:535–557.
  • NEWTON SM, LAU C, WRIGHT CW: A review of antimycobacterial natural products. Phytother. Res. (2000) 14:303–322.
  • NCAYIYANA DJ: Africa can solve its own health problems. Br. Med. (2002) 324:688–689.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.